HFpEF - Mechanisms and management - Dr Alexander Lyon Ver más
Cardiology Update 2016 Meeting organised by St George's, University of London - 2nd December 2016, Royal Society of Art, London UK
Management of Heart Failure - Dissecting the new guidelines
HFpEF - Mechanisms and management
TRANSCRIPT
My name is Dr Alexander Lyon, I’m a senior lecturer at Imperial College, London, UK, and a honorary consultant cardiologist at the Royal Brompton Hospital in London. I’m also a member of the Heart Failure Association Board with specialist interest in cardio-oncology and heart failure caused by cancer drugs, and also Takotsubo syndrome and stress and the interaction of heart failure.
Which were the most salient aspects of your talk?
I had the privilege and challenge of discussing heart failure with preserved ejection fraction (HFpEF) which is a growing clinical problem for our health care services, but we’re limited in terms of our understanding of this condition and therefore how we can treat it.
I reviewed some of the information about some of the mechanisms. I personally believe there are many different subtypes of this condition. So whereas with heart failure with reduced ejection fraction patients we’ve had success using some common treatments across them all irrespective of etiology, when we move into HFpEF we haven’t been successful with the ‘one size fits all’ common pathways.
So therefore we need to do more research to understand particular types of patients, not least related to their comorbidities. So I discussed how comorbidities are and the different ‘flavours’ of HFpEF, and from that then we can start to understand the biology of each one, and personalise treatment approaches.
And I finished by giving some real world advice on what we can do with the patients today whilst we still need further research on how to manage the patient of tomorrow better.
Prevalence of CVD and Assessment of CV Risk in Patients with Prostate Cancer Ver más
Dr. Alexander Lyon presented “Prevalence of CVD and Assessment of CV Risk in Patients with Prostate Cancer” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.